Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Hideyuki Niwa; Sakiko Otani; Norihiro Nakada; Jiichiro Sasaki; Hideo Saka; Noriyuki Masuda

doi:10.1016/j.rmcr.2018.01.006

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Hideyuki Niwa
, Sakiko Otani
, Norihiro Nakada
, Jiichiro Sasaki
, Hideo Saka
, Noriyuki Masuda

Research output: Contribution to journal › Article › peer-review

Abstract

Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.

Original language	English
Pages (from-to)	131-135
Number of pages	5
Journal	Respiratory Medicine Case Reports
Volume	23
DOIs	https://doi.org/10.1016/j.rmcr.2018.01.006
Publication status	Published - 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.rmcr.2018.01.006

Cite this

@article{ae1df331d1f64aadad2bb4bf104b10b5,

title = "Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report",

abstract = "Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.",

keywords = "Carboplatin, Carcinosarcoma, Chemotherapy, Interstitial lung disease, Nab-paclitaxel",

author = "Hideyuki Niwa and Sakiko Otani and Norihiro Nakada and Jiichiro Sasaki and Hideo Saka and Noriyuki Masuda",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2018",

doi = "10.1016/j.rmcr.2018.01.006",

language = "English",

volume = "23",

pages = "131--135",

journal = "Respiratory Medicine Case Reports",

issn = "2213-0071",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease

T2 - A case report

AU - Niwa, Hideyuki

AU - Otani, Sakiko

AU - Nakada, Norihiro

AU - Sasaki, Jiichiro

AU - Saka, Hideo

AU - Masuda, Noriyuki

PY - 2018

Y1 - 2018

N2 - Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.

AB - Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD.

KW - Carboplatin

KW - Carcinosarcoma

KW - Chemotherapy

KW - Interstitial lung disease

KW - Nab-paclitaxel

UR - https://www.scopus.com/pages/publications/85042918622

UR - https://www.scopus.com/pages/publications/85042918622#tab=citedBy

U2 - 10.1016/j.rmcr.2018.01.006

DO - 10.1016/j.rmcr.2018.01.006

M3 - Article

AN - SCOPUS:85042918622

SN - 2213-0071

VL - 23

SP - 131

EP - 135

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

ER -

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this